CJC-1295 / Ipamorelin 5/5mg is a dual-peptide research formulation currently being evaluated in laboratory settings for its interaction with endogenous growth hormone regulatory pathways.
CJC-1295 is a growth hormone–releasing hormone (GHRH) analog studied for its role in stimulating pituitary signaling associated with growth hormone modulation.
Ipamorelin is a selective growth hormone secretagogue investigated for its interaction with the ghrelin receptor (GHS-R1a), contributing to downstream endocrine signaling processes.
Research models have explored their combined influence on:
• Growth hormone signaling dynamics
• IGF-1 regulatory pathways
• Metabolic system interactions
• Circadian-associated hormonal rhythms
Scientific findings remain preliminary and highly dependent on study design, dosing structure, and experimental conditions.